Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous blinatumomab in relapsed/refractory or MRD-positive B-cell precursor acute lymphoblastic leukemia
2023-506136-32-00Phase 2Suspended
- Sponsor
- Amgen
- Start
- Oct 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 2, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) and B cell acute lymphoblastic leukemia (B-ALL) (6 arms), sponsored by Amgen. Primary endpoints: Dose escalation safety, Dose expansion efficacy and 3 more. Started Oct 2020; status: suspended.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on 2023-506136-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506136-32-00.